nejm glp 1 Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes This NEJM Perspective highlights a

The formulations themselves have also evolved considerably since the WHI era

The specific product, manufacturer and clinical purpose matter more than declaring one marketing category the universal winner

Studies indicate that it effectively scavenges ROS and enhances the expression of endogenous antioxidant enzymes, such as SOD and catalase

Severe, persistent upper abdominal pain radiating to the back, accompanied by nausea and vomiting, requires immediate medical assessment and discontinuation of the medication

Tip: Eating smaller, protein-rich meals and staying hydrated can significantly reduce GI discomfort

What to do: Before starting any GLP-1 medication , ensure you have had a thorough thyroid evaluation including thyroid ultrasound